Occlutech is a well-established, privately-held medical device company with a global commercial footprint, having implanted over 220,000 of its occluder devices in over 70 countries. Its core business is built on a proven portfolio of minimally invasive implants for structural heart interventions, including devices for patent foramen ovale (PFO), atrial septal defects (ASD), and patent ductus arteriosus (PDA). The company is now advancing its growth strategy through clinical development of a novel Atrial Flow Regulator (AFR) device for heart failure and pulmonary hypertension, positioning it in large, high-need therapeutic markets.
Minimally invasive cardiac implant platform utilizing self-expanding nitinol frames for occlusion and regulated interatrial shunting.
Funding History
3
Total raised:$75M
Series C$40MUndisclosed
Series B$25MUndisclosed
Series A$10MUndisclosed
Opportunities
The Atrial Flow Regulator addresses massive unmet needs in heart failure, particularly HFpEF, which lacks device therapies, representing a multi-billion dollar market.
Successful clinical results could transform the company from a structural heart specialist into a major player in the high-growth heart failure device segment.
The established global commercial infrastructure provides a significant advantage for launching new products.
Risk Factors
Clinical failure of the pivotal FROST-HF trial would jeopardize the AFR's regulatory approval and commercial viability.
The company faces intense competition in the evolving heart failure device space from larger medtech firms and other shunt technologies.
Regulatory hurdles and slower-than-expected physician adoption for a novel therapy pose significant commercial execution risks.
Competitive Landscape
In occluders, Occlutech competes with giants like Abbott (Amplatzer) and smaller specialized firms. In heart failure, the AFR will compete against other interatrial shunt devices (e.g., Edwards Lifesciences' IASD, V-Wave's shunt) and a broader array of heart failure therapies from major pharmaceutical and device companies, making differentiation through clinical data critical.
